Next Article in Journal
Paroxysmal Dystonic Posturing Mimicking Nocturnal Leg Cramps as a Presenting Sign in an Infant with DCC Mutation, Callosal Agenesis and Mirror Movements
Previous Article in Journal
Updated Clinical Practice Guidelines in Resuscitation and the Management of Respiratory Distress Syndrome in Extremely Preterm Infants during Two Epochs in Romania: Impact on Outcomes
Previous Article in Special Issue
Medication-Related Hospital Admissions and Emergency Department Visits in Older People with Diabetes: A Systematic Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 13
Issue 4
10.3390/jcm13041107
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related Biomarkers

by
Justyna Rentflejsz
1,2,* and
Zyta Beata Wojszel
2
1
Doctoral School, Medical University of Bialystok, 15-089 Bialystok, Poland
2
Department of Geriatrics, Medical University of Bialystok, 15-471 Bialystok, Poland
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2024, 13(4), 1107; https://doi.org/10.3390/jcm13041107
Submission received: 11 December 2023 / Revised: 2 February 2024 / Accepted: 11 February 2024 / Published: 15 February 2024
(This article belongs to the Special Issue The Challenge of Healthy Aging with Diabetes)
Review Reports Versions Notes

Abstract

:
Sarcopenia is a chronic, progressive skeletal muscle disease characterised by low muscle strength and quantity or quality, leading to low physical performance. Patients with type 2 diabetes mellitus (T2DM) are more at risk of sarcopenia than euglycemic individuals. Because of several shared pathways between the two diseases, sarcopenia is also a risk factor for developing T2DM in older patients. Various biomarkers are under investigation as potentially valuable for sarcopenia diagnosis and treatment monitoring. Biomarkers related to sarcopenia can be divided into markers evaluating musculoskeletal status (biomarkers specific to muscle mass, markers of the neuromuscular junction, or myokines) and markers assuming causal factors (adipokines, hormones, and inflammatory markers). This paper reviews the current knowledge about how diabetes and T2DM complications affect potential sarcopenia biomarker concentrations. This review includes markers recently proposed by the expert group of the European Society for the Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) as those that may currently be useful in phase II and III clinical trials of sarcopenia: myostatin (MSTN); follistatin (FST); irisin; brain-derived neurotrophic factor (BDNF); procollagen type III N-terminal peptide (PIIINP; P3NP); sarcopenia index (serum creatinine to serum cystatin C ratio); adiponectin; leptin; insulin-like growth factor-1 (IGF-1); dehydroepiandrosterone sulphate (DHEAS); C-reactive protein (CRP); interleukin-6 (IL-6), and tumor necrosis factor α (TNF-α). A better understanding of factors influencing these biomarkers’ levels, including diabetes and diabetic complications, may lead to designing future studies and implementing results in clinical practice.

1. Sarcopenia: Definition and Epidemiology

Sarcopenia is a chronic, progressive skeletal muscle disease characterised by low muscle strength and mass and worse muscle quality, leading to low physical performance—a hallmark of severe sarcopenia [1]. Its presence significantly worsens prognosis and is related to a higher risk of polypharmacy [2], impaired quality of life [3], falls and fractures [4], loss of physical independence [5], and death [6]. It is a common disorder affecting approximately 10% to 27% of the population aged ≥60 years, depending on the criteria and methods used for diagnosis. The prevalence of severe sarcopenia—a situation in which low muscle mass and strength are accompanied by impaired physical fitness—ranges from 2% to 9% [7]. The frequency of sarcopenia in nursing homes is higher than in community-dwelling older adults and is estimated at 51% in men and 31% in women [8].
Over the years, many well-established scientific groups have proposed different definitions and diagnostic criteria for sarcopenia in search of a tool with supreme sensitivity [9]. Five major research groups have been working to provide a precise description: the European Working Group on Sarcopenia in Older People (EWGSOP), the Asia Working Group for Sarcopenia (AWGS), the International Working Group on Sarcopenia (IWGS), Society for Sarcopenia Cachexia and Wasting Disorders (SCWD), and the Foundation for the National Institutes of Health (FNIH) Sarcopenia Project [1,10,11,12,13,14,15]. Because of that, different cut-off points and definitions applied in the diagnosis of sarcopenia, established over time, may affect the results of previously conducted research.
Currently, the diagnosis of sarcopenia is based on a clinical algorithm proposed by the EWGSOP2 Group in its very latest consensus on sarcopenia. Screening assessment involves using the SARC-F scale. The next step is measuring hand grip strength (or performing a Chair Stand Test) to diagnose low muscle strength, followed by estimating muscle quantity with dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), magnetic resonance imaging (MRI), or computed tomography (CT). In addition, physical performance tests, such as the Timed-Up-and-Go test (TUG), Short Physical Performance Battery (SPPB), gait speed measurement, and 400 m Walk Test are used to evaluate patients for severe sarcopenia [1].
Apart from the above-mentioned anatomic biomarkers of sarcopenia, several specific biochemical biomarkers have been proposed, to be used first of all in research and clinical trials of drugs developed for sarcopenia treatment [16]. They can help to increase knowledge about the mode of action of medications, monitor their effectiveness and side effects, and establish surrogate endpoints [17].

2. Type 2 Diabetes and Sarcopenia

Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterised by hyperglycemia determined by insulin resistance and impaired insulin secretion. Patients with T2DM are at higher risk of sarcopenia than euglycemic individuals [18,19,20,21,22,23,24], especially when diabetes complications develop. Diabetic peripheral neuropathy is considered an independent risk factor for sarcopenia in T2DM patients [25]. Similarly, albuminuria is related to sarcopenia in older subjects with T2DM in a dose-related manner, and the risk starts even from minimal albuminuria [26,27]. In a recent meta-analysis by Ai and co-workers, the prevalence of sarcopenia among T2DM subjects was estimated at 18% (95% CI 15–22%), and older age, osteoporosis, and chronic hyperglycemia (measured with HbA1c levels) were significant risk factors. At the same time, lower BMI and metformin administration were protective elements [28].
Generally, poor glycemic control in patients with T2DM was linked to low skeletal muscle mass [29]. Some studies even reported it as the leading risk factor for sarcopenia in diabetes, independently of diabetes type or insulin treatment [30]. Still, the effects of anti-diabetic medications on sarcopenia are unclear and need further studies [31,32]. Amongst T2DM patients, those with incident sarcopenia have worse islet function, insufficient insulin secretion, and more significant blood glucose fluctuations than non-sarcopenic patients [33,34,35,36]. In addition, higher body fat content was associated with sarcopenia in older adults with T2DM [37].
Researchers suggest that T2DM and sarcopenia might have a bidirectional causal influence on each other [38,39,40], so sarcopenia can also be a risk factor for developing T2DM in older populations [41]. Furthermore, a study by Huang et al. found 15 common genes and several shared pathways between two diseases [42]. Insulin resistance, mitochondrial dysfunction, advanced glycation end-products (AGEs) and glycogen metabolism, oxidative stress, chronic systemic inflammation, and many other mechanisms play essential roles in the pathogenesis of both sarcopenia and T2DM [43,44]. Sarcopenia might also affect T2DM through decreased production of myokines [45]. Myokines are peptides produced, expressed, and released by muscle fibers that elicit autocrine, paracrine, or endocrine effects [46]. Myokines facilitate communication between muscles and other organs and, among others, can affect lipid and glucose metabolism. Thanks to some myokines’ regulative function, physical exercise may improve insulin sensitivity, but it still needs to be established whether training can enhance insulin secretion [47].

3. Biomarkers of Sarcopenia

The early diagnosis of sarcopenia is essential for the success of the therapeutic intervention. However, the diagnostic process is complex and requires specialised equipment. Therefore, the search for alternative diagnostic instruments continues, with attempts to implement biomarker concentrations in advancing the diagnostic process [48,49,50,51,52]. Furthermore, in clinical trials assessing medications to treat sarcopenia, measuring specific biomarker concentrations could help monitor early therapeutic response [16]. Unfortunately, the pathogenesis of sarcopenia includes various complex molecular mechanisms and is not yet fully understood [53]. Therefore, according to the EWGSOP2 group, it is unlikely that one single biomarker could be specific enough to diagnose it, so there is a need to develop a panel of biomarkers instead that could be used for scientific and clinical purposes [1].
According to Atkinson and coworkers, a biomarker is “a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention” [54]. Biomarkers related to sarcopenia can be divided into two groups:
  • Markers evaluating musculoskeletal status (those specific to muscle mass, markers of the neuromuscular junction, muscle turnover, and myokines);
  • Markers evaluating causal factors for sarcopenia (adipokines, hormones, and inflammatory parameters) [16].
Unfortunately, sarcopenia patients can suffer from many comorbidities that may simultaneously affect biomarker concentrations. As it turns out, one of the critical influencing factors that should be considered is T2DM.
The paper aims to present how diabetes and its complications can potentially affect sarcopenia-related biochemical marker concentrations. This short review concentrates on biomarkers that the expert group of the European Society for the Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) has suggested recently as those that may currently be useful in phase II and III clinical trials of sarcopenia [16]. The main findings are summarised in Table 1.

3.1. Diabetes and Myokines

3.1.1. Myostatin

Myostatin (MSTN), or growth differentiation factor-8 (GDF-8), is a negative regulatory protein of muscle growth. Most studies show that higher myostatin levels are associated with higher muscle mass or function. Yet research results are inconsistent; some studies only found a male-specific association (or no association). Different metabolic profiles and comorbidities might be the reason for these conflicting data results [55]. Studies suggest that MSTN may promote the progression of obesity and diabetes through its effects on skeletal muscle and other non-muscle tissues (adipose tissue, liver) [106]. GDF-8 influences lipid metabolism and can promote intracellular lipid accumulation in muscles by upregulating the expressions of some genes (CD36, PPARγ) [107].
In animal models, diabetic mice’s bones revealed an overexpression of myostatin [108]. Further animal studies showed that decreased myostatin expression improved glucose uptake even in diabetes [109,110]. Moreover, myostatin inhibition caused a reduction in blood glucose, insulin, and triglyceride levels and improved insulin sensitivity [111].
In human studies, mean plasma myostatin levels were significantly higher in patients with T2DM [56,57] and subjects with metabolic syndrome and impaired glucose–insulin homeostasis with lower muscle mass [112]. However, some studies showed that T2DM subjects had significantly lower myostatin concentrations, and MSTN was negatively related to blood fasting glucose and triglyceride levels [113]. The weakness of the studies mentioned above is a limited number of participants (ranging from 44 to 128 subjects only). Further studies assessing myostatin levels with larger numbers of T2DM participants need to be performed in order to establish the biomarker’s significance in this specific group.
A study by Li et al. indicated that among patients with T2DM, myostatin levels were significantly higher in subjects with sarcopenia [114]; however, the study only included 34 sarcopenic individuals (meeting the criteria of the Asian sarcopenia diagnostic consensus). Exercise programs decrease MSTN concentrations in T2DM patients [57,115]. Myostatin concentration levels were also positively associated with diabetic retinopathy [116]. Higher levels of muscle myostatin mRNA content were found in T2DM patients. However, plasma myostatin concentrations did not differ between subjects with diabetes and controls [117].
Children with type 1 diabetes mellitus (T1DM) exhibited significantly elevated serum myostatin levels compared to healthy subjects in some studies [118,119]. On the other hand, gestational diabetes does not influence cord blood myostatin levels [120]; however, it affects myostatin protein expression in placentae [121].

3.1.2. Follistatin

Follistatin (FST) acts as an antagonist of transforming growth factor-β (TGF-β) ligands (including myostatin and activin A), which is why MSTN and FST should be considered together. Follistatin concentrations seemed to be elevated in patients with sarcopenia, as was indicated in a large cross-sectional study of community-dwelling postmenopausal women [58], yet some studies showed no correlation between this myokine and muscle health [122,123,124]. Still, it is worth mentioning that in one of these studies, follistatin levels tended to be negatively correlated with muscle mass, with borderline statistical significance, and significantly correlated in female patients [122], and the other two mentioned studies had relatively small sample sizes.
In animal models, intravascular FST gene administration to prediabetic and diabetic mice improved glycaemic control and promoted compensatory insulinemia [125]. Human studies indicated plasma FST levels increase in T2DM patients [59,60]. In an observational study by Wu et al., subjects who developed T2DM during follow-up had higher FST concentrations at baseline, suggesting that increased FST levels were associated with a higher risk of diabetes [126]. In T2DM patients, exercising was connected with increasing follistatin levels [115]; nonetheless, exercise-induced FST secretion seemed to be impaired in patients with T2DM [127].

3.1.3. Irisin

Irisin is a myokine that induces muscle hypertrophy. Its concentrations were found to be decreased in sarcopenic patients [61,62,63,64,65,66], but some studies found no correlation between the two [128,129]. There are multiple studies proving irisin levels are significantly lower in patients with T2DM (including a meta-analysis published in 2016 and involving 1745 diabetic patients and 1337 controls from 17 cross-sectional and 6 case–control studies [67] and another published in 2021 [68] and evaluating 26 studies with a total of 3667 participants), yet some studies show the opposite correlation [113,130]. Nevertheless, we must underline that studies with the opposite results involved much fewer participants (73 diabetic individuals with 55 controls and 104 T2DM subjects with 124 controls, respectively).
Decreased irisin concentrations in T2DM patients are observed in parallel with cardiovascular complications [131,132,133]. They may have some predictive value in heart failure diagnosis [134,135] and be linked to nephropathy [136]. Some interventions, like sitagliptin treatment, increase serum irisin levels in T2DM patients [137].

3.2. Diabetes and Markers of the Neuromuscular Junction and Neuroinflammation

Brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) are markers associated with the neuromuscular junction and neuroinflammation. These are neurotrophins released from both neurons and muscles and play an essential role in muscle development and metabolism and the regulation of synapse function [138]. Research on these neurotrophins’ levels in sarcopenia is limited. In a Japanese study of haemodialysis patients, BDNF concentrations were lower in subjects with severe sarcopenia and frailty [69]. Another study showed an association of lower BDNF levels with a low skeletal muscle index (SMI) in kidney transplant recipients [70]. In other studies, plasma concentrations of BDNF were higher in more advanced stages of sarcopenia [139]. Both BDNF and GDNF were shown to potentially play a role in the diagnosis of sarcopenia in chronic obstructive pulmonary disease (COPD) and Parkinson’s disease (PD) patients [140,141]. A recent meta-analysis of 28 studies, including 2734 diabetic individuals and over 6000 controls, revealed significantly decreased BDNF concentrations in T2DM subjects and patients with diabetic retinopathy compared to controls [71].

3.3. Diabetes and Procollagen Type III N-Terminal Peptide

Procollagen type III N-terminal peptide (PIIINP; P3NP) is produced during type III collagen synthesis. Its concentrations seem to be related to aging, body composition, and physical performance [142,143]. The evidence of its role in sarcopenia is yet to be established. One study showed an association between higher PIIINP levels and lower lean body mass in postmenopausal women [72], yet in another study, PIIINP concentrations were associated with an increased SMI in men [73]. These discrepancies might be related to steroid hormones levels, as some studies found that testosterone may increase plasma PIIINP levels in a dose-dependent manner [144] and higher PIIINP concentrations induced by testosterone treatment were related to greater gains in skeletal muscle mass in older males [145].
The PIIINP levels increase with higher BMI and age [146], but there seems to be no significant correlation between them and diabetes [74]. On the other hand, they might be associated with diabetes-related complications such as proliferative retinopathy [147] and peripheral vascular disease [148].

3.4. Diabetes and Sarcopenia Index

Sarcopenia index (SI; serum creatinine to serum cystatin C ratio) is a recently developed formula for evaluating muscle mass [149]. Serum creatinine concentrations reflect muscle protein turnover but are also determined by renal function. That is why, in this formula, creatinine level is related to another marker of renal function—cystatin C.
SI has been correlated with CT skeletal muscle cross-sectional surface area [149,150,151], calf circumference, BMI, handgrip strength [152], and gait speed [153]. In some studies, SI was found not to be accurate enough to diagnose sarcopenia in community-dwelling older individuals [154,155], but there was evidence of its accuracy in hospitalised older patients [75,76].
Some studies suggested that in T2DM patients, SI could be a valuable screening sarcopenia marker [156,157]. It was also related to subclinical atherosclerosis [158] and increased risk of fractures [159] in T2DM subjects, as well as to osteoporosis in T2DM male patients [160]. A low serum creatinine-to-cystatin C ratio was associated with a higher risk of all-cause mortality in diabetic patients [161]. A higher SI normalised by body weight was associated with a reduced risk of T2DM in middle-aged and older subjects [77].

3.5. Diabetes and Adipokines

Adiponectin is an adipokine with insulin-sensitising and anti-inflammatory effects. Reducing body fat leads to increased adiponectin blood concentrations [162]. Although several research results were conflicting, a recent meta-analysis (involving six cross-sectional and one retrospective study with a total number of 1389 participants) confirmed that circulating adiponectin levels were higher in sarcopenic patients, and the female sex significantly influenced the results. These greater plasma adiponectin concentrations, independent of BMI or fat mass, might be explained partially by sex hormones. It is discussed that adiponectin could play a role in a compensatory mechanism for mitigating sarcopenia resulting from chronic inflammation and oxidative stress [78]. Lower adiponectin levels were associated with T2DM and metabolic syndrome [79]. The decrease in adiponectinemia was a risk factor in the pathogenesis of insulin resistance, T2DM, and cardiovascular pathologies [162]. In in vitro studies on skeletal muscle cells, adiponectin increased glucose uptake by translocating the glucose transporter GLUT4 to the cell surface [163]. The activation of muscle protein degradation via the ubiquitin–proteasome proteolytic pathway mediated by insulin resistance may result from reduced adiponectin levels [164].
Leptin is an adipokine that, among other things, improves immune response and induces lipid catabolism [165]. Some studies showed leptin levels were elevated in sarcopenic patients [80,81]. Nevertheless, research in this area yields conflicting data. A study by Lin et al. indicated that lower serum leptin concentrations were independently associated with sarcopenia in haemodialysis patients [82]. The weakness of these studies is a limited number of participants. Another study of community-dwelling older adults showed a positive association of leptin serum levels with muscle and fat mass and negative with muscle strength—increased leptin levels were linked to a higher risk of dynapenia (low muscle strength), but a lower risk of sarcopenia [83]. In addition, patients with sarcopenic obesity have higher leptin and lower adiponectin levels compared to sarcopenic non-obese subjects [166]. Leptin concentrations in sarcopenic individuals, specifically in patients with sarcopenic obesity and in sarcopenic T2DM patients, need further studies.
Leptin levels seem to be increased in individuals with obesity [167] as well as in diabetic patients [84,85,86,87]. Yet, some studies found such an association only in obese T2DM patients (in a study by Liu et al., leptin concentrations were significantly lower in newly diagnosed T2DM patients with normal BMI than healthy individuals but considerably higher in obese T2DM patients) [168]. Elevated leptin concentrations may be related to insulin resistance in diabetic patients [169,170,171]. Leptin was also higher in T2DM patients with diabetic complications [172,173]. Although some studies suggested a difference in leptin concentrations between men and women [174,175], a recent meta-analysis of 10 studies with more than thirty thousand diabetic participants in total concluded gender factors did not affect leptin levels in T2DM patients [176]. In addition, many other factors may influence leptin levels in T2DM patients, for example, some anti-diabetic medications [177,178].

3.6. Diabetes and Hormones

Insulin-like growth factor (IGF-1) regulates muscle anabolic and catabolic pathways, inhibiting muscle atrophy and potentiating muscle regeneration [179]. IGF-1 concentrations seem to be higher in younger subjects [123], and the age-related decline in IGF-1 levels is considered a possible factor contributing to the development of sarcopenia [180]. There is evidence of decreased levels of IGF-1 in sarcopenic patients [88,89,90,91,92], yet a study by Jiang and co-workers found such an association only in men [181].
Decreased IGF-1 concentrations were also reported in patients with T2DM [93,94]. However, some studies found no association between IGF-1 levels and incident diabetes in the general population [95], and studies that associated low IGF-1 levels with diabetes in young adults did not confirm such an association in subjects over 65 years of age [96]. In contrast, a survey by Shao and colleagues found significantly higher IGF-1 levels in T2DM patients compared to the control group, and IGF-1 concentrations increased with a more significant level of albuminuria [97]. This might suggest that different comorbidities and diabetic complications can alter IGF-1 concentrations. Elevated levels of IGF-1 were found in older patients with dementia and diabetes [182], yet in another study, lower IGF-1 levels were a predictor of poor cognitive performance in patients with diabetes [183]. In T2DM subjects with relatively reasonable glycaemic control, increased IGF-1 was related to a higher risk of retinopathy progression [184]. On the other hand, another study of T2DM patients revealed lower IGF-1 concentrations in subjects with T2DM complicated by coronary heart disease [185].
Dehydroepiandrosterone sulphate (DHEAS) is a steroid hormone, a testosterone precursor. Its role in sarcopenia has long been studied, and the age-related decrease in its levels is perceived as a causal factor for muscle loss. DHEAS concentrations correlate positively with older patients’ skeletal muscle mass and strength and seem to be decreased in sarcopenic individuals [58,98,99]. Exercise and nutritional supplementation can increase DHEAS levels in older adults, and this effect is more pronounced in frail participants [186]. Among T2DM patients, those with sarcopenia have significantly decreased DHEAS levels [187].
Study results suggest that serum DHEAS concentrations are negatively associated with the risk of T2DM [100,101], although some studies indicate that DHEAS levels have no association with incident diabetes in women [101,188]. In a study with a 5-year follow-up, the decline in DHEAS was especially significant in subjects who became diabetic [102]; another study revealed that higher DHEAS concentrations at baseline were a protective factor against developing T2DM in older men (but not in older women) [189]. Lower DHEAS levels were associated with poor diabetes control [190]. In addition, DHEAS levels correlated inversely with the degree of urinary albumin excretion in T2DM male patients [191] and with the duration of diabetes [192]. Decreased DHEAS concentrations in T2DM patients were also associated with diabetic retinopathy [193], atherosclerosis [194,195], diabetic kidney disease [196], and coronary heart disease in diabetic men [197].

3.7. Diabetes and Inflammatory Markers

One of the crucial mechanisms that may be related to sarcopenia pathogenesis is chronic inflammation. Inflammatory cytokines have been linked to muscle wasting, promoting protein catabolism and suppressing muscle tissue synthesis. A meta-analysis published in 2016 indicated that sarcopenia is associated with increased C-reactive protein (CRP) levels but did not confirm the association between sarcopenia and interleukin-6 (IL-6) or tumour necrosis factor α (TNF-α) concentrations [103]. Nevertheless, a more recent meta-analysis with the significantly greater number of articles analysed, concluded that increased CRP, IL-6, and TNF-α levels were significantly associated with lower skeletal muscle strength and muscle mass [198].
Elevated levels of inflammatory markers were also linked to an increased risk of T2DM, as confirmed in large meta-analyses [104,105]. Additionally, T2DM patients with depression or cognitive impairment seem to have elevated IL-6 and CRP levels compared to diabetic subjects without comorbidities [199,200]. However, several interventions in T2DM patients, such as diabetes medications or exercise training, can decrease inflammatory biomarker concentrations. Metformin administration reduces CRP (but not TNFα or IL-6) levels [201]. Exercise decreases CRP, TNFα, and IL-6 in diabetic patients [202,203,204].

4. Conclusions

Sarcopenia and type 2 diabetes are chronic diseases that affect many older people. Their pathogeneses are interconnected, and their impact is bidirectional—each is a risk factor for the other. Both diseases share several common determinant genes and common pathogenetic pathways. The assessment of serum concentrations of various biomarkers may provide new information about these pathomechanisms and help develop new tools for rapid diagnosis and monitoring sarcopenia treatment.
This brief review shows that using a single biomarker concentration to diagnose or monitor sarcopenia would be insufficient because of different factors influencing its levels. In some cases, the results of available studies are inconsistent and potential reasons for discrepancies include variations in study design, differences in sample sizes, or distinct characteristics of the study populations. What is more, most of the biomarkers presented require further studies to assess their levels in patients with various comorbidities. These include, among others, diabetes status, the level of glycaemic control, diabetes complications, and glucose-lowering medications. Therefore, diabetes mellitus should be considered an important confounding factor in future analyses of studies designed to assess levels of sarcopenia-related biomarkers.
Further studies should be designed to develop a set of biomarkers that would be suitable for monitoring sarcopenia and its treatment in T2DM patients. This may result in a better understanding of the factors influencing the concentration of various biomarkers in serum and establish their usefulness in clinical practice.

Author Contributions

Conceptualisation, J.R. and Z.B.W.; methodology, J.R.; software, J.R. and Z.B.W.; validation, J.R. and Z.B.W.; formal analysis, J.R. and Z.B.W.; investigation, J.R.; resources, J.R. and Z.B.W.; data curation, J.R. and Z.B.W.; writing—original draft preparation, J.R.; writing—review and editing, Z.B.W.; visualisation, J.R.; supervision, Z.B.W.; project administration, J.R. and Z.B.W.; funding acquisition, J.R. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by the Medical University of Bialystok, grant number B.SUB.24.188. The financial sponsor played no role in the design, execution, analysis, and interpretation of data.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing 2019, 48, 601. [Google Scholar] [CrossRef] [PubMed]
  2. Prokopidis, K.; Giannos, P.; Reginster, J.Y.; Bruyere, O.; Petrovic, M.; Cherubini, A.; Triantafyllidis, K.K.; Kechagias, K.S.; Dionyssiotis, Y.; Cesari, M.; et al. Sarcopenia is associated with a greater risk of polypharmacy and number of medications: A systematic review and meta-analysis. J. Cachexia Sarcopenia Muscle 2023, 14, 671–683. [Google Scholar] [CrossRef] [PubMed]
  3. Beaudart, C.; Demonceau, C.; Reginster, J.Y.; Locquet, M.; Cesari, M.; Cruz Jentoft, A.J.; Bruyère, O. Sarcopenia and health-related quality of life: A systematic review and meta-analysis. J. Cachexia Sarcopenia Muscle 2023, 14, 1228–1243. [Google Scholar] [CrossRef] [PubMed]
  4. Yeung, S.S.Y.; Reijnierse, E.M.; Pham, V.K.; Trappenburg, M.C.; Lim, W.K.; Meskers, C.G.M.; Maier, A.B. Sarcopenia and its association with falls and fractures in older adults: A systematic review and meta-analysis. J. Cachexia Sarcopenia Muscle 2019, 10, 485–500. [Google Scholar] [CrossRef] [PubMed]
  5. Dos Santos, L.; Cyrino, E.S.; Antunes, M.; Santos, D.A.; Sardinha, L.B. Sarcopenia and physical independence in older adults: The independent and synergic role of muscle mass and muscle function. J. Cachexia Sarcopenia Muscle 2017, 8, 245–250. [Google Scholar] [CrossRef] [PubMed]
  6. Xu, J.; Wan, C.S.; Ktoris, K.; Reijnierse, E.M.; Maier, A.B. Sarcopenia Is Associated with Mortality in Adults: A Systematic Review and Meta-Analysis. Gerontology 2022, 68, 361–376. [Google Scholar] [CrossRef] [PubMed]
  7. Petermann-Rocha, F.; Balntzi, V.; Gray, S.R.; Lara, J.; Ho, F.K.; Pell, J.P.; Celis-Morales, C. Global prevalence of sarcopenia and severe sarcopenia: A systematic review and meta-analysis. J. Cachexia Sarcopenia Muscle 2022, 13, 86–99. [Google Scholar] [CrossRef] [PubMed]
  8. Papadopoulou, S.K.; Tsintavis, P.; Potsaki, P.; Papandreou, D. Differences in the Prevalence of Sarcopenia in Community-Dwelling, Nursing Home and Hospitalized Individuals. A Systematic Review and Meta-Analysis. J. Nutr. Health Aging 2020, 24, 83–90. [Google Scholar] [CrossRef]
  9. Giovannini, S.; Brau, F.; Forino, R.; Berti, A.; D’Ignazio, F.; Loreti, C.; Bellieni, A.; D’Angelo, E.; Di Caro, F.; Biscotti, L.; et al. Sarcopenia: Diagnosis and Management, State of the Art and Contribution of Ultrasound. J. Clin. Med. 2021, 10, 5552. [Google Scholar] [CrossRef]
  10. Cruz-Jentoft, A.J.; Baeyens, J.P.; Bauer, J.M.; Boirie, Y.; Cederholm, T.; Landi, F.; Martin, F.C.; Michel, J.P.; Rolland, Y.; Schneider, S.M.; et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010, 39, 412–423. [Google Scholar] [CrossRef]
  11. Chen, L.K.; Liu, L.K.; Woo, J.; Assantachai, P.; Auyeung, T.W.; Bahyah, K.S.; Chou, M.Y.; Chen, L.Y.; Hsu, P.S.; Krairit, O.; et al. Sarcopenia in Asia: Consensus report of the Asian Working Group for Sarcopenia. J. Am. Med. Dir. Assoc. 2014, 15, 95–101. [Google Scholar] [CrossRef]
  12. Chen, L.K.; Woo, J.; Assantachai, P.; Auyeung, T.W.; Chou, M.Y.; Iijima, K.; Jang, H.C.; Kang, L.; Kim, M.; Kim, S.; et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J. Am. Med. Dir. Assoc. 2020, 21, 300–307.e302. [Google Scholar] [CrossRef]
  13. Fielding, R.A.; Vellas, B.; Evans, W.J.; Bhasin, S.; Morley, J.E.; Newman, A.B.; Abellan van Kan, G.; Andrieu, S.; Bauer, J.; Breuille, D.; et al. Sarcopenia: An undiagnosed condition in older adults. Current consensus definition: Prevalence, etiology, and consequences. International working group on sarcopenia. J. Am. Med. Dir. Assoc. 2011, 12, 249–256. [Google Scholar] [CrossRef]
  14. Morley, J.E.; Abbatecola, A.M.; Argiles, J.M.; Baracos, V.; Bauer, J.; Bhasin, S.; Cederholm, T.; Coats, A.J.; Cummings, S.R.; Evans, W.J.; et al. Sarcopenia with limited mobility: An international consensus. J. Am. Med. Dir. Assoc. 2011, 12, 403–409. [Google Scholar] [CrossRef] [PubMed]
  15. Studenski, S.A.; Peters, K.W.; Alley, D.E.; Cawthon, P.M.; McLean, R.R.; Harris, T.B.; Ferrucci, L.; Guralnik, J.M.; Fragala, M.S.; Kenny, A.M.; et al. The FNIH sarcopenia project: Rationale, study description, conference recommendations, and final estimates. J. Gerontol. A Biol. Sci. Med. Sci. 2014, 69, 547–558. [Google Scholar] [CrossRef] [PubMed]
  16. Ladang, A.; Beaudart, C.; Reginster, J.Y.; Al-Daghri, N.; Bruyère, O.; Burlet, N.; Cesari, M.; Cherubini, A.; da Silva, M.C.; Cooper, C.; et al. Biochemical Markers of Musculoskeletal Health and Aging to be Assessed in Clinical Trials of Drugs Aiming at the Treatment of Sarcopenia: Consensus Paper from an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Centre Académique de Recherche et d’Expérimentation en Santé (CARES SPRL), Under the Auspices of the World Health Organization Collaborating Center for the Epidemiology of Musculoskeletal Conditions and Aging. Calcif. Tissue Int. 2023, 112, 197–217. [Google Scholar] [CrossRef] [PubMed]
  17. Selleck, M.J.; Senthil, M.; Wall, N.R. Making Meaningful Clinical Use of Biomarkers. Biomark. Insights 2017, 12, 1177271917715236. [Google Scholar] [CrossRef]
  18. Anagnostis, P.; Gkekas, N.K.; Achilla, C.; Pananastasiou, G.; Taouxidou, P.; Mitsiou, M.; Kenanidis, E.; Potoupnis, M.; Tsiridis, E.; Goulis, D.G. Type 2 Diabetes Mellitus is Associated with Increased Risk of Sarcopenia: A Systematic Review and Meta-analysis. Calcif. Tissue Int. 2020, 107, 453–463. [Google Scholar] [CrossRef] [PubMed]
  19. Izzo, A.; Massimino, E.; Riccardi, G.; Della Pepa, G. A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors. Nutrients 2021, 13, 183. [Google Scholar] [CrossRef]
  20. Qiao, Y.S.; Chai, Y.H.; Gong, H.J.; Zhuldyz, Z.; Stehouwer, C.D.A.; Zhou, J.B.; Simó, R. The Association Between Diabetes Mellitus and Risk of Sarcopenia: Accumulated Evidences From Observational Studies. Front Endocrinol. 2021, 12, 782391. [Google Scholar] [CrossRef]
  21. Mori, H.; Kuroda, A.; Yoshida, S.; Yasuda, T.; Umayahara, Y.; Shimizu, S.; Ryomoto, K.; Yoshiuchi, K.; Yamamoto, T.; Matsuoka, T.A.; et al. High prevalence and clinical impact of dynapenia and sarcopenia in Japanese patients with type 1 and type 2 diabetes: Findings from the Impact of Diabetes Mellitus on Dynapenia study. J. Diabetes Investig. 2021, 12, 1050–1059. [Google Scholar] [CrossRef] [PubMed]
  22. Wang, T.; Feng, X.; Zhou, J.; Gong, H.; Xia, S.; Wei, Q.; Hu, X.; Tao, R.; Li, L.; Qian, F.; et al. Type 2 diabetes mellitus is associated with increased risks of sarcopenia and pre-sarcopenia in Chinese elderly. Sci. Rep. 2016, 6, 38937. [Google Scholar] [CrossRef] [PubMed]
  23. Velázquez-Alva, M.C.; Irigoyen-Camacho, M.E.; Zepeda-Zepeda, M.A.; Lazarevich, I.; Arrieta-Cruz, I.; D’Hyver, C. Sarcopenia, nutritional status and type 2 diabetes mellitus: A cross-sectional study in a group of Mexican women residing in a nursing home. Nutr. Diet. 2020, 77, 515–522. [Google Scholar] [CrossRef] [PubMed]
  24. Trierweiler, H.; Kisielewicz, G.; Hoffmann Jonasson, T.; Rasmussen Petterle, R.; Aguiar Moreira, C.; Zeghbi Cochenski Borba, V. Sarcopenia: A chronic complication of type 2 diabetes mellitus. Diabetol. Metab. Syndr. 2018, 10, 25. [Google Scholar] [CrossRef] [PubMed]
  25. Yang, Q.; Zhang, Y.; Zeng, Q.; Yang, C.; Shi, J.; Zhang, C.; Ni, X.; Du, Z.; Tang, Z.; Hu, J.; et al. Correlation Between Diabetic Peripheral Neuropathy and Sarcopenia in Patients with Type 2 Diabetes Mellitus and Diabetic Foot Disease: A Cross-Sectional Study. Diabetes Metab. Syndr. Obes. 2020, 13, 377–386. [Google Scholar] [CrossRef]
  26. Chang, C.J.; Lin, C.H.; Hsieh, H.M.; Lo, W.Y.; Lai, Y.H.; Peng, L.N.; Chen, L.K. Risk of sarcopenia among older persons with Type 2 diabetes mellitus with different status of albuminuria: A dose-responsive association. Arch. Gerontol. Geriatr. 2021, 95, 104338. [Google Scholar] [CrossRef]
  27. Pechmann, L.M.; Jonasson, T.H.; Canossa, V.S.; Trierweiler, H.; Kisielewicz, G.; Petterle, R.R.; Moreira, C.A.; Borba, V.Z.C. Sarcopenia in Type 2 Diabetes Mellitus: A Cross-Sectional Observational Study. Int. J. Endocrinol. 2020, 2020, 7841390. [Google Scholar] [CrossRef]
  28. Ai, Y.; Xu, R.; Liu, L. The prevalence and risk factors of sarcopenia in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetol. Metab. Syndr. 2021, 13, 93. [Google Scholar] [CrossRef]
  29. Sugimoto, K.; Tabara, Y.; Ikegami, H.; Takata, Y.; Kamide, K.; Ikezoe, T.; Kiyoshige, E.; Makutani, Y.; Onuma, H.; Gondo, Y.; et al. Hyperglycemia in non-obese patients with type 2 diabetes is associated with low muscle mass: The Multicenter Study for Clarifying Evidence for Sarcopenia in Patients with Diabetes Mellitus. J. Diabetes Investig. 2019, 10, 1471–1479. [Google Scholar] [CrossRef] [PubMed]
  30. Hiromine, Y.; Noso, S.; Rakugi, H.; Sugimoto, K.; Takata, Y.; Katsuya, T.; Fukuda, M.; Akasaka, H.; Osawa, H.; Tabara, Y.; et al. Poor glycemic control rather than types of diabetes is a risk factor for sarcopenia in diabetes mellitus: The MUSCLES-DM study. J. Diabetes Investig. 2022, 13, 1881–1888. [Google Scholar] [CrossRef] [PubMed]
  31. Ma, X.Y.; Chen, F.Q. Effects of anti-diabetic drugs on sarcopenia: Best treatment options for elderly patients with type 2 diabetes mellitus and sarcopenia. World J. Clin. Cases 2021, 9, 10064–10074. [Google Scholar] [CrossRef]
  32. Umegaki, H. Sarcopenia and frailty in older patients with diabetes mellitus. Geriatr. Gerontol. Int. 2016, 16, 293–299. [Google Scholar] [CrossRef] [PubMed]
  33. Lin, Y.; Zhang, Y.; Shen, X.; Huang, L.; Yan, S. Influence of glucose, insulin fluctuation, and glycosylated hemoglobin on the outcome of sarcopenia in patients with type 2 diabetes mellitus. J. Diabetes Complicat. 2021, 35, 107926. [Google Scholar] [CrossRef]
  34. Ma, G.C.; Zou, L.L.; Dai, W.; Wang, Z.Z.; Cao, Y.H. The association between glucose fluctuation with sarcopenia in elderly patients with type 2 diabetes mellitus. Eur. Rev. Med. Pharmacol. Sci. 2023, 27, 1912–1920. [Google Scholar] [CrossRef] [PubMed]
  35. Ogama, N.; Sakurai, T.; Kawashima, S.; Tanikawa, T.; Tokuda, H.; Satake, S.; Miura, H.; Shimizu, A.; Kokubo, M.; Niida, S.; et al. Association of Glucose Fluctuations with Sarcopenia in Older Adults with Type 2 Diabetes Mellitus. J. Clin. Med. 2019, 8, 319. [Google Scholar] [CrossRef]
  36. Tanaka, K.; Kanazawa, I.; Sugimoto, T. Reduction in Endogenous Insulin Secretion is a Risk Factor of Sarcopenia in Men with Type 2 Diabetes Mellitus. Calcif. Tissue Int. 2015, 97, 385–390. [Google Scholar] [CrossRef] [PubMed]
  37. Sun, L.; Fu, J.; Mu, Z.; Duan, X.; Chan, P.; Xiu, S. Association between body fat and sarcopenia in older adults with type 2 diabetes mellitus: A cross-sectional study. Front. Endocrinol. 2023, 14, 1094075. [Google Scholar] [CrossRef]
  38. Chen, S.; Yan, S.; Aiheti, N.; Kuribanjiang, K.; Yao, X.; Wang, Q.; Zhou, T.; Yang, L. A bi-directional Mendelian randomization study of sarcopenia-related traits and type 2 diabetes mellitus. Front. Endocrinol. 2023, 14, 1109800. [Google Scholar] [CrossRef]
  39. Mesinovic, J.; Scott, D. Sarcopenia and diabetes mellitus: Evidence for a bi-directional relationship. Eur. Geriatr. Med. 2019, 10, 677–680. [Google Scholar] [CrossRef]
  40. Veronese, N.; Pizzol, D.; Demurtas, J.; Soysal, P.; Smith, L.; Sieber, C.; Strandberg, T.; Bourdel-Marchasson, I.; Sinclair, A.; Petrovic, M.; et al. Association between sarcopenia and diabetes: A systematic review and meta-analysis of observational studies. Eur. Geriatr. Med. 2019, 10, 685–696. [Google Scholar] [CrossRef]
  41. Koo, B.K.; Roh, E.; Yang, Y.S.; Moon, M.K. Difference between old and young adults in contribution of β-cell function and sarcopenia in developing diabetes mellitus. J. Diabetes Investig. 2016, 7, 233–240. [Google Scholar] [CrossRef] [PubMed]
  42. Huang, S.; Xiang, C.; Song, Y. Identification of the shared gene signatures and pathways between sarcopenia and type 2 diabetes mellitus. PLoS ONE 2022, 17, e0265221. [Google Scholar] [CrossRef] [PubMed]
  43. Landi, F.; Onder, G.; Bernabei, R. Sarcopenia and diabetes: Two sides of the same coin. J. Am. Med. Dir. Assoc. 2013, 14, 540–541. [Google Scholar] [CrossRef]
  44. Chen, L.K. The vicious cycle in the development of diabetes mellitus and sarcopenia in older persons. Arch. Gerontol. Geriatr. 2021, 95, 104437. [Google Scholar] [CrossRef]
  45. Purnamasari, D.; Tetrasiwi, E.N.; Kartiko, G.J.; Astrella, C.; Husam, K.; Laksmi, P.W. Sarcopenia and Chronic Complications of Type 2 Diabetes Mellitus. Rev. Diabet. Stud. 2022, 18, 157–165. [Google Scholar] [CrossRef] [PubMed]
  46. Pedersen, B.K.; Steensberg, A.; Fischer, C.; Keller, C.; Keller, P.; Plomgaard, P.; Febbraio, M.; Saltin, B. Searching for the exercise factor: Is IL-6 a candidate? J. Muscle Res. Cell Motil. 2003, 24, 113–119. [Google Scholar] [CrossRef]
  47. Severinsen, M.C.K.; Pedersen, B.K. Muscle-Organ Crosstalk: The Emerging Roles of Myokines. Endocr. Rev. 2020, 41, 594–609. [Google Scholar] [CrossRef]
  48. Lu, L.; Liu, B.; Yin, F. Alternative skeletal muscle index for sarcopenia diagnosis in elderly patients with type 2 diabetes mellitus: A pilot study. Front. Endocrinol. 2023, 14, 1083722. [Google Scholar] [CrossRef]
  49. Picca, A.; Calvani, R.; Cesari, M.; Landi, F.; Bernabei, R.; Coelho-Júnior, H.J.; Marzetti, E. Biomarkers of Physical Frailty and Sarcopenia: Coming up to the Place? Int. J. Mol. Sci. 2020, 21, 5635. [Google Scholar] [CrossRef]
  50. Calvani, R.; Picca, A.; Marini, F.; Biancolillo, A.; Gervasoni, J.; Persichilli, S.; Primiano, A.; Coelho-Junior, H.J.; Cesari, M.; Bossola, M.; et al. Identification of biomarkers for physical frailty and sarcopenia through a new multi-marker approach: Results from the BIOSPHERE study. Geroscience 2021, 43, 727–740. [Google Scholar] [CrossRef]
  51. Qaisar, R.; Karim, A.; Muhammad, T.; Shah, I.; Khan, J. Prediction of sarcopenia using a battery of circulating biomarkers. Sci. Rep. 2021, 11, 8632. [Google Scholar] [CrossRef] [PubMed]
  52. Ying, L.; Zhang, Q.; Yang, Y.M.; Zhou, J.Y. A Combination of Serum Biomarkers in Elderly Patients with Sarcopenia: A Cross-Sectional Observational Study. Int. J. Endocrinol. 2022, 2022, 4026940. [Google Scholar] [CrossRef] [PubMed]
  53. Mankhong, S.; Kim, S.; Moon, S.; Kwak, H.B.; Park, D.H.; Kang, J.H. Experimental Models of Sarcopenia: Bridging Molecular Mechanism and Therapeutic Strategy. Cells 2020, 9, 1385. [Google Scholar] [CrossRef]
  54. Biomarkers Definitions Working, G. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69, 89–95. [Google Scholar] [CrossRef]
  55. Baczek, J.; Silkiewicz, M.; Wojszel, Z.B. Myostatin as a Biomarker of Muscle Wasting and other Pathologies-State of the Art and Knowledge Gaps. Nutrients 2020, 12, 2401. [Google Scholar] [CrossRef]
  56. Wang, F.; Liao, Y.; Li, X.; Ren, C.; Cheng, C.; Ren, Y. Increased circulating myostatin in patients with type 2 diabetes mellitus. J. Huazhong Univ. Sci. Technol. Med. Sci. 2012, 32, 534–539. [Google Scholar] [CrossRef]
  57. Shabkhiz, F.; Khalafi, M.; Rosenkranz, S.; Karimi, P.; Moghadami, K. Resistance training attenuates circulating FGF-21 and myostatin and improves insulin resistance in elderly men with and without type 2 diabetes mellitus: A randomised controlled clinical trial. Eur. J. Sport Sci. 2021, 21, 636–645. [Google Scholar] [CrossRef] [PubMed]
  58. Du, Y.; Xu, C.; Shi, H.; Jiang, X.; Tang, W.; Wu, X.; Chen, M.; Li, H.; Zhang, X.; Cheng, Q. Serum concentrations of oxytocin, DHEA and follistatin are associated with osteoporosis or sarcopenia in community-dwelling postmenopausal women. BMC Geriatr. 2021, 21, 542. [Google Scholar] [CrossRef]
  59. Hansen, J.; Rinnov, A.; Krogh-Madsen, R.; Fischer, C.P.; Andreasen, A.S.; Berg, R.M.; Møller, K.; Pedersen, B.K.; Plomgaard, P. Plasma follistatin is elevated in patients with type 2 diabetes: Relationship to hyperglycemia, hyperinsulinemia, and systemic low-grade inflammation. Diabetes Metab. Res. Rev. 2013, 29, 463–472. [Google Scholar] [CrossRef]
  60. Sylow, L.; Vind, B.F.; Kruse, R.; Møller, P.M.; Wojtaszewski, J.F.P.; Richter, E.A.; Højlund, K. Circulating Follistatin and Activin A and Their Regulation by Insulin in Obesity and Type 2 Diabetes. J. Clin. Endocrinol. Metab. 2020, 105, dgaa090. [Google Scholar] [CrossRef]
  61. Alsaawi, T.A.; Aldisi, D.; Abulmeaty, M.M.A.; Khattak, M.N.K.; Alnaami, A.M.; Sabico, S.; Al-Daghri, N.M. Screening for Sarcopenia among Elderly Arab Females: Influence of Body Composition, Lifestyle, Irisin, and Vitamin D. Nutrients 2022, 14, 1855. [Google Scholar] [CrossRef]
  62. Oflazoglu, U.; Caglar, S.; Yılmaz, H.E.; Önal, H.T.; Varol, U.; Salman, T.; Yildiz, Y.; Unal, S.; Guc, Z.G.; Kucukzeybek, Y.; et al. The relationship between sarcopenia detected in newly diagnosed colorectal cancer patients and FGF21, irisin and CRP levels. Eur. Geriatr. Med. 2022, 13, 795–803. [Google Scholar] [CrossRef]
  63. Zhao, M.; Zhou, X.; Yuan, C.; Li, R.; Ma, Y.; Tang, X. Association between serum irisin concentrations and sarcopenia in patients with liver cirrhosis: A cross-sectional study. Sci. Rep. 2020, 10, 16093. [Google Scholar] [CrossRef]
  64. Park, H.S.; Kim, H.C.; Zhang, D.; Yeom, H.; Lim, S.K. The novel myokine irisin: Clinical implications and potential role as a biomarker for sarcopenia in postmenopausal women. Endocrine 2019, 64, 341–348. [Google Scholar] [CrossRef]
  65. Chang, J.S.; Kim, T.H.; Nguyen, T.T.; Park, K.S.; Kim, N.; Kong, I.D. Circulating irisin levels as a predictive biomarker for sarcopenia: A cross-sectional community-based study. Geriatr. Gerontol. Int. 2017, 17, 2266–2273. [Google Scholar] [CrossRef]
  66. Oguz, A.; Sahin, M.; Tuzun, D.; Kurutas, E.B.; Ulgen, C.; Bozkus, O.; Gul, K. Irisin is a predictor of sarcopenic obesity in type 2 diabetes mellitus: A cross-sectional study. Medcine 2021, 100, e26529. [Google Scholar] [CrossRef]
  67. Du, X.L.; Jiang, W.X.; Lv, Z.T. Lower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis. Horm. Metab. Res. 2016, 48, 644–652. [Google Scholar] [CrossRef]
  68. Song, R.; Zhao, X.; Zhang, D.Q.; Wang, R.; Feng, Y. Lower levels of irisin in patients with type 2 diabetes mellitus: A meta-analysis. Diabetes Res. Clin. Pract. 2021, 175, 108788. [Google Scholar] [CrossRef] [PubMed]
  69. Miyazaki, S.; Iino, N.; Koda, R.; Narita, I.; Kaneko, Y. Brain-derived neurotrophic factor is associated with sarcopenia and frailty in Japanese hemodialysis patients. Geriatr. Gerontol. Int. 2021, 21, 27–33. [Google Scholar] [CrossRef] [PubMed]
  70. Koito, Y.; Yanishi, M.; Kimura, Y.; Tsukaguchi, H.; Kinoshita, H.; Matsuda, T. Serum Brain-Derived Neurotrophic Factor and Myostatin Levels Are Associated With Skeletal Muscle Mass in Kidney Transplant Recipients. Transplant. Proc. 2021, 53, 1939–1944. [Google Scholar] [CrossRef] [PubMed]
  71. Moosaie, F.; Mohammadi, S.; Saghazadeh, A.; Dehghani Firouzabadi, F.; Rezaei, N. Brain-derived neurotrophic factor in diabetes mellitus: A systematic review and meta-analysis. PLoS ONE 2023, 18, e0268816. [Google Scholar] [CrossRef] [PubMed]
  72. Berry, S.D.; Ramachandran, V.S.; Cawthon, P.M.; Gona, P.; McLean, R.R.; Cupples, L.A.; Kiel, D.P. Procollagen type III N-terminal peptide (P3NP) and lean mass: A cross-sectional study. J. Frailty Aging 2013, 2, 129–134. [Google Scholar] [CrossRef]
  73. Chen, Y.Y.; Chiu, Y.L.; Kao, T.W.; Peng, T.C.; Yang, H.F.; Chen, W.L. Cross-sectional associations among P3NP, HtrA, Hsp70, Apelin and sarcopenia in Taiwanese population. BMC Geriatr. 2021, 21, 192. [Google Scholar] [CrossRef]
  74. Wang, T.J.; Larson, M.G.; Benjamin, E.J.; Siwik, D.A.; Safa, R.; Guo, C.Y.; Corey, D.; Sundstrom, J.; Sawyer, D.B.; Colucci, W.S.; et al. Clinical and echocardiographic correlates of plasma procollagen type III amino-terminal peptide levels in the community. Am. Heart J. 2007, 154, 291–297. [Google Scholar] [CrossRef]
  75. Ren, C.; Su, H.; Tao, J.; Xie, Y.; Zhang, X.; Guo, Q. Sarcopenia Index Based on Serum Creatinine and Cystatin C is Associated with Mortality, Nutritional Risk/Malnutrition and Sarcopenia in Older Patients. Clin. Interv. Aging 2022, 17, 211–221. [Google Scholar] [CrossRef] [PubMed]
  76. Ge, J.; Zeng, J.; Ma, H.; Sun, S.; Zhao, Z.; Jing, Y.; Qian, C.; Fei, Z.; Cui, R.; Qu, S.; et al. A New Index Based on Serum Creatinine and Cystatin C Can Predict the Risks of Sarcopenia, Falls and Fractures in Old Patients with Low Bone Mineral Density. Nutrients 2022, 14, 5020. [Google Scholar] [CrossRef]
  77. Qiu, S.; Cai, X.; Xie, B.; Yuan, Y.; Sun, Z.; Wu, T. Normalized Creatinine-to-Cystatin C Ratio and Risk of Diabetes in Middle-Aged and Older Adults: The China Health and Retirement Longitudinal Study. Diabetes Metab. J. 2022, 46, 476–485. [Google Scholar] [CrossRef] [PubMed]
  78. Komici, K.; Dello Iacono, A.; De Luca, A.; Perrotta, F.; Bencivenga, L.; Rengo, G.; Rocca, A.; Guerra, G. Adiponectin and Sarcopenia: A Systematic Review With Meta-Analysis. Front. Endocrinol. 2021, 12, 576619. [Google Scholar] [CrossRef]
  79. Frankenberg, A.D.V.; Reis, A.F.; Gerchman, F. Relationships between adiponectin levels, the metabolic syndrome, and type 2 diabetes: A literature review. Arch. Endocrinol. Metab. 2017, 61, 614–622. [Google Scholar] [CrossRef]
  80. Waters, D.L.; Qualls, C.R.; Dorin, R.I.; Veldhuis, J.D.; Baumgartner, R.N. Altered growth hormone, cortisol, and leptin secretion in healthy elderly persons with sarcopenia and mixed body composition phenotypes. J. Gerontol. A Biol. Sci. Med. Sci. 2008, 63, 536–541. [Google Scholar] [CrossRef]
  81. Li, C.W.; Yu, K.; Shyh-Chang, N.; Li, G.X.; Jiang, L.J.; Yu, S.L.; Xu, L.Y.; Liu, R.J.; Guo, Z.J.; Xie, H.Y.; et al. Circulating factors associated with sarcopenia during ageing and after intensive lifestyle intervention. J. Cachexia Sarcopenia Muscle 2019, 10, 586–600. [Google Scholar] [CrossRef]
  82. Lin, Y.L.; Wang, C.H.; Lai, Y.H.; Kuo, C.H.; Syu, R.J.; Hsu, B.G. Negative correlation between leptin serum levels and sarcopenia in hemodialysis patients. Int. J. Clin. Exp. Pathol. 2018, 11, 1715–1723. [Google Scholar]
  83. Kao, T.W.; Peng, T.C.; Chen, W.L.; Chi, Y.C.; Chen, C.L.; Yang, W.S. Higher Serum Leptin Levels are Associated with a Reduced Risk of Sarcopenia but a Higher Risk of Dynapenia Among Older Adults. J. Inflamm. Res. 2021, 14, 5817–5825. [Google Scholar] [CrossRef]
  84. Szekeres, Z.; Sandor, B.; Bognar, Z.; Ramadan, F.H.J.; Palfi, A.; Bodis, B.; Toth, K.; Szabados, E. Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes. Int. J. Mol. Sci. 2023, 24, 4405. [Google Scholar] [CrossRef]
  85. Wang, L.K.; Wang, H.; Wu, X.L.; Shi, L.; Yang, R.M.; Wang, Y.C. Relationships among resistin, adiponectin, and leptin and microvascular complications in patients with type 2 diabetes mellitus. J. Int. Med. Res. 2020, 48, 300060519870407. [Google Scholar] [CrossRef]
  86. Diwan, A.G.; Kuvalekar, A.A.; Dharamsi, S.; Vora, A.M.; Nikam, V.A.; Ghadge, A.A. Correlation of Serum Adiponectin and Leptin levels in Obesity and Type 2 Diabetes Mellitus. Indian. J. Endocrinol. Metab. 2018, 22, 93–99. [Google Scholar] [CrossRef]
  87. Al-Hamodi, Z.; Al-Habori, M.; Al-Meeri, A.; Saif-Ali, R. Association of adipokines, leptin/adiponectin ratio and C-reactive protein with obesity and type 2 diabetes mellitus. Diabetol. Metab. Syndr. 2014, 6, 99. [Google Scholar] [CrossRef] [PubMed]
  88. Bian, A.; Ma, Y.; Zhou, X.; Guo, Y.; Wang, W.; Zhang, Y.; Wang, X. Association between sarcopenia and levels of growth hormone and insulin-like growth factor-1 in the elderly. BMC Musculoskelet. Disord. 2020, 21, 214. [Google Scholar] [CrossRef] [PubMed]
  89. Saeki, C.; Kanai, T.; Nakano, M.; Oikawa, T.; Torisu, Y.; Saruta, M.; Tsubota, A. Low Serum Branched-Chain Amino Acid and Insulin-Like Growth Factor-1 Levels Are Associated with Sarcopenia and Slow Gait Speed in Patients with Liver Cirrhosis. J. Clin. Med. 2020, 9, 3239. [Google Scholar] [CrossRef]
  90. Hata, S.; Mori, H.; Yasuda, T.; Irie, Y.; Yamamoto, T.; Umayahara, Y.; Ryomoto, K.; Yoshiuchi, K.; Yoshida, S.; Shimomura, I.; et al. A low serum IGF-1 is correlated with sarcopenia in subjects with type 1 diabetes mellitus: Findings from a post-hoc analysis of the iDIAMOND study. Diabetes Res. Clin. Pract. 2021, 179, 108998. [Google Scholar] [CrossRef]
  91. Widajanti, N.; Soelistijo, S.; Hadi, U.; Thaha, M.; Aditiawardana; Widodo; Firdausi, H.; Nurina, Y.; Asikin, M.; Srinowati, H.; et al. Association between Sarcopenia and Insulin-Like Growth Factor-1, Myostatin, and Insulin Resistance in Elderly Patients Undergoing Hemodialysis. J. Aging Res. 2022, 2022, 1327332. [Google Scholar] [CrossRef]
  92. Petermann-Rocha, F.; Gray, S.R.; Pell, J.P.; Celis-Morales, C.; Ho, F.K. Biomarkers Profile of People With Sarcopenia: A Cross-sectional Analysis From UK Biobank. J. Am. Med. Dir. Assoc. 2020, 21, 2017.e2011–2017.e2019. [Google Scholar] [CrossRef]
  93. Efstratiadis, G.; Tsiaousis, G.; Athyros, V.G.; Karagianni, D.; Pavlitou-Tsiontsi, A.; Giannakou-Darda, A.; Manes, C. Total serum insulin-like growth factor-1 and C-reactive protein in metabolic syndrome with or without diabetes. Angiology 2006, 57, 303–311. [Google Scholar] [CrossRef]
  94. He, S.; He, Y.; Jin, F.; Liu, Y. Correlation analysis of IGF-1, ZAG, nesfatin-1, HbA1c levels, and type 2 diabetes mellitus complicated with hypothyroidism. Medcine 2021, 100, e25432. [Google Scholar] [CrossRef]
  95. Drogan, D.; Schulze, M.B.; Boeing, H.; Pischon, T. Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor-Binding Protein 3 in Relation to the Risk of Type 2 Diabetes Mellitus: Results From the EPIC-Potsdam Study. Am. J. Epidemiol. 2016, 183, 553–560. [Google Scholar] [CrossRef]
  96. Teppala, S.; Shankar, A. Association between serum IGF-1 and diabetes among U.S. adults. Diabetes Care 2010, 33, 2257–2259. [Google Scholar] [CrossRef] [PubMed]
  97. Shao, Y.; Lv, C.; Yuan, Q.; Wang, Q. Levels of Serum 25(OH)VD3, HIF-1α, VEGF, vWf, and IGF-1 and Their Correlation in Type 2 Diabetes Patients with Different Urine Albumin Creatinine Ratio. J. Diabetes Res. 2016, 2016, 1925424. [Google Scholar] [CrossRef]
  98. Valenti, G.; Denti, L.; Maggio, M.; Ceda, G.; Volpato, S.; Bandinelli, S.; Ceresini, G.; Cappola, A.; Guralnik, J.M.; Ferrucci, L. Effect of DHEAS on skeletal muscle over the life span: The InCHIANTI study. J. Gerontol. A Biol. Sci. Med. Sci. 2004, 59, 466–472. [Google Scholar] [CrossRef] [PubMed]
  99. Hwang, A.C.; Liu, L.K.; Lee, W.J.; Chen, L.Y.; Lin, M.H.; Peng, L.N.; Won, C.W.; Chen, L.K. Association of androgen with skeletal muscle mass and muscle function among men and women aged 50 years and older in Taiwan: Results from the I-Lan longitudinal aging study. Rejuvenation Res. 2013, 16, 453–459. [Google Scholar] [CrossRef]
  100. Brahimaj, A.; Muka, T.; Kavousi, M.; Laven, J.S.; Dehghan, A.; Franco, O.H. Serum dehydroepiandrosterone levels are associated with lower risk of type 2 diabetes: The Rotterdam Study. Diabetologia 2017, 60, 98–106. [Google Scholar] [CrossRef]
  101. Hu, J.; Zhang, A.; Yang, S.; Wang, Y.; Goswami, R.; Zhou, H.; Zhang, Y.; Wang, Z.; Li, R.; Cheng, Q.; et al. Combined effects of sex hormone-binding globulin and sex hormones on risk of incident type 2 diabetes. J. Diabetes 2016, 8, 508–515. [Google Scholar] [CrossRef]
  102. Kameda, W.; Daimon, M.; Oizumi, T.; Jimbu, Y.; Kimura, M.; Hirata, A.; Yamaguchi, H.; Ohnuma, H.; Igarashi, M.; Tominaga, M.; et al. Association of decrease in serum dehydroepiandrosterone sulfate levels with the progression to type 2 diabetes in men of a Japanese population: The Funagata Study. Metabolism 2005, 54, 669–676. [Google Scholar] [CrossRef]
  103. Bano, G.; Trevisan, C.; Carraro, S.; Solmi, M.; Luchini, C.; Stubbs, B.; Manzato, E.; Sergi, G.; Veronese, N. Inflammation and sarcopenia: A systematic review and meta-analysis. Maturitas 2017, 96, 10–15. [Google Scholar] [CrossRef]
  104. Wang, X.; Bao, W.; Liu, J.; Ouyang, Y.Y.; Wang, D.; Rong, S.; Xiao, X.; Shan, Z.L.; Zhang, Y.; Yao, P.; et al. Inflammatory markers and risk of type 2 diabetes: A systematic review and meta-analysis. Diabetes Care 2013, 36, 166–175. [Google Scholar] [CrossRef]
  105. Liu, C.; Feng, X.; Li, Q.; Wang, Y.; Hua, M. Adiponectin, TNF-α and inflammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis. Cytokine 2016, 86, 100–109. [Google Scholar] [CrossRef]
  106. Allen, D.L.; Hittel, D.S.; McPherron, A.C. Expression and function of myostatin in obesity, diabetes, and exercise adaptation. Med. Sci. Sports Exerc. 2011, 43, 1828–1835. [Google Scholar] [CrossRef] [PubMed]
  107. Lee, E.J.; Ahmad, S.S.; Lim, J.H.; Ahmad, K.; Shaikh, S.; Lee, Y.S.; Park, S.J.; Jin, J.O.; Lee, Y.H.; Choi, I. Interaction of Fibromodulin and Myostatin to Regulate Skeletal Muscle Aging: An Opposite Regulation in Muscle Aging, Diabetes, and Intracellular Lipid Accumulation. Cells 2021, 10, 2083. [Google Scholar] [CrossRef] [PubMed]
  108. Wallner, C.; Jaurich, H.; Wagner, J.M.; Becerikli, M.; Harati, K.; Dadras, M.; Lehnhardt, M.; Behr, B. Inhibition of GDF8 (Myostatin) accelerates bone regeneration in diabetes mellitus type 2. Sci. Rep. 2017, 7, 9878. [Google Scholar] [CrossRef] [PubMed]
  109. Li, B.; Cui, W.; Yang, J. Enhanced skeletal muscle growth in myostatin-deficient transgenic pigs had improved glucose uptake in stretozotocin-induced diabetes. Transgenic Res. 2020, 29, 253–261. [Google Scholar] [CrossRef] [PubMed]
  110. Coleman, S.K.; Rebalka, I.A.; D’Souza, D.M.; Deodhare, N.; Desjardins, E.M.; Hawke, T.J. Myostatin inhibition therapy for insulin-deficient type 1 diabetes. Sci. Rep. 2016, 6, 32495. [Google Scholar] [CrossRef] [PubMed]
  111. Guo, T.; Bond, N.D.; Jou, W.; Gavrilova, O.; Portas, J.; McPherron, A.C. Myostatin inhibition prevents diabetes and hyperphagia in a mouse model of lipodystrophy. Diabetes 2012, 61, 2414–2423. [Google Scholar] [CrossRef] [PubMed]
  112. Carvalho, L.P.; Basso-Vanelli, R.P.; Di Thommazo-Luporini, L.; Mendes, R.G.; Oliveira-Junior, M.C.; Vieira, R.P.; Bonjorno-Junior, J.C.; Oliveira, C.R.; Luporini, R.; Borghi-Silva, A. Myostatin and adipokines: The role of the metabolically unhealthy obese phenotype in muscle function and aerobic capacity in young adults. Cytokine 2018, 107, 118–124. [Google Scholar] [CrossRef]
  113. García-Fontana, B.; Reyes-García, R.; Morales-Santana, S.; Ávila-Rubio, V.; Muñoz-Garach, A.; Rozas-Moreno, P.; Muñoz-Torres, M. Relationship between myostatin and irisin in type 2 diabetes mellitus: A compensatory mechanism to an unfavourable metabolic state? Endocrine 2016, 52, 54–62. [Google Scholar] [CrossRef]
  114. Li, X.; Kong, X.; Li, R. Correlation between lipoprotein(a), albuminuria, myostatin and sarcopenia in elderly patients with type 2 diabetes. J. Diabetes Complicat. 2023, 37, 108382. [Google Scholar] [CrossRef]
  115. Motahari Rad, M.; Bijeh, N.; Attarzadeh Hosseini, S.R.; Raouf Saeb, A. The effect of two concurrent exercise modalities on serum concentrations of FGF21, irisin, follistatin, and myostatin in men with type 2 diabetes mellitus. Arch. Physiol. Biochem. 2023, 129, 424–433. [Google Scholar] [CrossRef]
  116. Chung, J.O.; Park, S.Y.; Chung, D.J.; Chung, M.Y. Serum myostatin levels are positively associated with diabetic retinopathy in individuals with type 2 diabetes mellitus. J. Diabetes Complicat. 2020, 34, 107592. [Google Scholar] [CrossRef]
  117. Brandt, C.; Nielsen, A.R.; Fischer, C.P.; Hansen, J.; Pedersen, B.K.; Plomgaard, P. Plasma and muscle myostatin in relation to type 2 diabetes. PLoS ONE 2012, 7, e37236. [Google Scholar] [CrossRef]
  118. Efthymiadou, A.; Vasilakis, I.A.; Giannakopoulos, A.; Chrysis, D. Myostatin serum levels in children with type 1 diabetes mellitus. Hormones 2021, 20, 777–782. [Google Scholar] [CrossRef]
  119. Dial, A.G.; Monaco, C.M.F.; Grafham, G.K.; Romanova, N.; Simpson, J.A.; Tarnopolsky, M.A.; Perry, C.G.R.; Kalaitzoglou, E.; Hawke, T.J. Muscle and serum myostatin expression in type 1 diabetes. Physiol. Rep. 2020, 8, e14500. [Google Scholar] [CrossRef]
  120. Huang, R.; Kibschull, M.; Briollais, L.; Pausova, Z.; Murphy, K.; Kingdom, J.; Lye, S.; Luo, Z.C. Cord blood myostatin concentrations by gestational diabetes mellitus and fetal sex. Front. Endocrinol. 2023, 14, 1018779. [Google Scholar] [CrossRef]
  121. Peiris, H.N.; Lappas, M.; Georgiou, H.M.; Vaswani, K.; Salomon, C.; Rice, G.E.; Mitchell, M.D. Myostatin in the placentae of pregnancies complicated with gestational diabetes mellitus. Placenta 2015, 36, 1–6. [Google Scholar] [CrossRef]
  122. Choi, K.; Jang, H.Y.; Ahn, J.M.; Hwang, S.H.; Chung, J.W.; Choi, Y.S.; Kim, J.W.; Jang, E.S.; Choi, G.H.; Jeong, S.H. The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma. Clin. Mol. Hepatol. 2020, 26, 492–505. [Google Scholar] [CrossRef]
  123. Hofmann, M.; Halper, B.; Oesen, S.; Franzke, B.; Stuparits, P.; Tschan, H.; Bachl, N.; Strasser, E.M.; Quittan, M.; Ploder, M.; et al. Serum concentrations of insulin-like growth factor-1, members of the TGF-beta superfamily and follistatin do not reflect different stages of dynapenia and sarcopenia in elderly women. Exp. Gerontol. 2015, 64, 35–45. [Google Scholar] [CrossRef]
  124. Negaresh, R.; Ranjbar, R.; Baker, J.S.; Habibi, A.; Mokhtarzade, M.; Gharibvand, M.M.; Fokin, A. Skeletal Muscle Hypertrophy, Insulin-like Growth Factor 1, Myostatin and Follistatin in Healthy and Sarcopenic Elderly Men: The Effect of Whole-body Resistance Training. Int. J. Prev. Med. 2019, 10, 29. [Google Scholar] [CrossRef]
  125. Davey, J.R.; Estevez, E.; Thomson, R.E.; Whitham, M.; Watt, K.I.; Hagg, A.; Qian, H.; Henstridge, D.C.; Ludlow, H.; Hedger, M.P.; et al. Intravascular Follistatin gene delivery improves glycemic control in a mouse model of type 2 diabetes. FASEB J. 2020, 34, 5697–5714. [Google Scholar] [CrossRef]
  126. Wu, C.; Borné, Y.; Gao, R.; López Rodriguez, M.; Roell, W.C.; Wilson, J.M.; Regmi, A.; Luan, C.; Aly, D.M.; Peter, A.; et al. Elevated circulating follistatin associates with an increased risk of type 2 diabetes. Nat. Commun. 2021, 12, 6486. [Google Scholar] [CrossRef]
  127. Hansen, J.S.; Pedersen, B.K.; Xu, G.; Lehmann, R.; Weigert, C.; Plomgaard, P. Exercise-Induced Secretion of FGF21 and Follistatin Are Blocked by Pancreatic Clamp and Impaired in Type 2 Diabetes. J. Clin. Endocrinol. Metab. 2016, 101, 2816–2825. [Google Scholar] [CrossRef]
  128. Baek, J.Y.; Jang, I.Y.; Jung, H.W.; Park, S.J.; Lee, J.Y.; Choi, E.; Lee, Y.S.; Lee, E.; Kim, B.J. Serum irisin level is independent of sarcopenia and related muscle parameters in older adults. Exp. Gerontol. 2022, 162, 111744. [Google Scholar] [CrossRef]
  129. Choi, H.Y.; Kim, S.; Park, J.W.; Lee, N.S.; Hwang, S.Y.; Huh, J.Y.; Hong, H.C.; Yoo, H.J.; Baik, S.H.; Youn, B.S.; et al. Implication of circulating irisin levels with brown adipose tissue and sarcopenia in humans. J. Clin. Endocrinol. Metab. 2014, 99, 2778–2785. [Google Scholar] [CrossRef]
  130. AlKhairi, I.; Cherian, P.; Abu-Farha, M.; Madhoun, A.A.; Nizam, R.; Melhem, M.; Jamal, M.; Al-Sabah, S.; Ali, H.; Tuomilehto, J.; et al. Increased Expression of Meteorin-Like Hormone in Type 2 Diabetes and Obesity and Its Association with Irisin. Cells 2019, 8, 1283. [Google Scholar] [CrossRef]
  131. Ahmed, T.M.; Nassar, M.; Mohamed, H.A.A.; Elhadidy, K.E.; Farhan, H.M.; El Basset, A.S.A.; Elmessiery, R.M.; Kamel, M.F. Evaluation of serum levels of Irisin as a marker of endothelial dysfunction in patients with type 2 diabetes mellitus. Endocrinol. Diabetes Metab. 2023, 6, e403. [Google Scholar] [CrossRef]
  132. Ali, E.Y.; Hegazy, G.A.; Hashem, E.M. Evaluation of irisin, retinol-binding protein 4, and leptin serum levels as biomarkers of macrovascular complications involvement in Saudi type 2 diabetes mellitus. A case-control study. Saudi Med. J. 2020, 41, 1369–1374. [Google Scholar] [CrossRef]
  133. El-Lebedy, D.H.; Ibrahim, A.A.; Ashmawy, I.O. Novel adipokines vaspin and irisin as risk biomarkers for cardiovascular diseases in type 2 diabetes mellitus. Diabetes Metab. Syndr. 2018, 12, 643–648. [Google Scholar] [CrossRef]
  134. Berezin, A.A.; Lichtenauer, M.; Boxhammer, E.; Stöhr, E.; Berezin, A.E. Discriminative Value of Serum Irisin in Prediction of Heart Failure with Different Phenotypes among Patients with Type 2 Diabetes Mellitus. Cells 2022, 11, 2794. [Google Scholar] [CrossRef]
  135. Berezin, A.A.; Obradovic, A.B.; Fushtey, I.M.; Berezina, T.A.; Lichtenauer, M.; Berezin, A.E. Low Plasma Levels of Irisin Predict Acutely Decompensated Heart Failure in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure. J. Cardiovasc. Dev. Dis. 2023, 10, 108788. [Google Scholar] [CrossRef]
  136. Wang, R.; Liu, H. Association Between Serum Irisin and Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis. Horm. Metab. Res. 2021, 53, 293–300. [Google Scholar] [CrossRef] [PubMed]
  137. Wang, Q.; Ma, L.; Zhang, Y.; Zhang, L.; An, Y.; Liu, J.; Wang, G. Effect of Sitagliptin on Serum Irisin Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. Diabetes Ther. 2021, 12, 1029–1039. [Google Scholar] [CrossRef]
  138. Moreira-Pais, A.; Ferreira, R.; Oliveira, P.A.; Duarte, J.A. A neuromuscular perspective of sarcopenia pathogenesis: Deciphering the signaling pathways involved. Geroscience 2022, 44, 1199–1213. [Google Scholar] [CrossRef]
  139. da Costa Teixeira, L.A.; Avelar, N.C.P.; Peixoto, M.F.D.; Parentoni, A.N.; Santos, J.M.D.; Pereira, F.S.M.; Danielewicz, A.L.; Leopoldino, A.A.O.; Costa, S.P.; Arrieiro, A.N.; et al. Inflammatory biomarkers at different stages of Sarcopenia in older women. Sci. Rep. 2023, 13, 10367. [Google Scholar] [CrossRef]
  140. Karim, A.; Muhammad, T.; Qaisar, R. Prediction of Sarcopenia Using Multiple Biomarkers of Neuromuscular Junction Degeneration in Chronic Obstructive Pulmonary Disease. J. Pers. Med. 2021, 11, 919. [Google Scholar] [CrossRef]
  141. Karim, A.; Iqbal, M.S.; Muhammad, T.; Qaisar, R. Evaluation of Sarcopenia Using Biomarkers of the Neuromuscular Junction in Parkinson’s Disease. J. Mol. Neurosci. 2022, 72, 820–829. [Google Scholar] [CrossRef]
  142. Pellegrino, R.; Paganelli, R.; Di Iorio, A.; Bandinelli, S.; Moretti, A.; Iolascon, G.; Sparvieri, E.; Tarantino, D.; Ferrucci, L. Muscle quality, physical performance, and comorbidity are predicted by circulating procollagen type III N-terminal peptide (P3NP): The InCHIANTI follow-up study. Geroscience 2023, 46, 1259–1269. [Google Scholar] [CrossRef]
  143. Shin, H.E.; Kim, M.; Won, C.W. Association between plasma procollagen type III N-terminal peptide (P3NP) levels and physical performance in elderly men: The Korean Frailty and Aging Cohort Study (KFACS). Exp. Gerontol. 2021, 154, 111523. [Google Scholar] [CrossRef]
  144. Chen, F.; Lam, R.; Shaywitz, D.; Hendrickson, R.C.; Opiteck, G.J.; Wishengrad, D.; Liaw, A.; Song, Q.; Stewart, A.J.; Cummings, C.E.; et al. Evaluation of early biomarkers of muscle anabolic response to testosterone. J. Cachexia Sarcopenia Muscle 2011, 2, 45–56. [Google Scholar] [CrossRef]
  145. Bhasin, S.; He, E.J.; Kawakubo, M.; Schroeder, E.T.; Yarasheski, K.; Opiteck, G.J.; Reicin, A.; Chen, F.; Lam, R.; Tsou, J.A.; et al. N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone. J. Clin. Endocrinol. Metab. 2009, 94, 4224–4233. [Google Scholar] [CrossRef]
  146. Barchetta, I.; Cimini, F.A.; De Gioannis, R.; Ciccarelli, G.; Bertoccini, L.; Lenzi, A.; Baroni, M.G.; Cavallo, M.G. Procollagen-III peptide identifies adipose tissue-associated inflammation in type 2 diabetes with or without nonalcoholic liver disease. Diabetes Metab. Res. Rev. 2018, 34, e2998. [Google Scholar] [CrossRef]
  147. Arkkila, P.E.; Rönnemaa, T.; Koskinen, P.J.; Kantola, I.M.; Seppänen, E.; Viikari, J.S. Biochemical markers of type III and I collagen: Association with retinopathy and neuropathy in type 1 diabetic subjects. Diabet. Med. 2001, 18, 816–821. [Google Scholar] [CrossRef]
  148. Migdalis, I.N.; Kalogeropoulou, K.; Zachariadis, D.; Koutoulidis, K.; Samartzis, M. Serum levels of type III procollagen peptide and peripheral vascular disease in diabetic patients. Diabetes Res. Clin. Pract. 1994, 23, 179–182. [Google Scholar] [CrossRef]
  149. Kashani, K.B.; Frazee, E.N.; Kukrálová, L.; Sarvottam, K.; Herasevich, V.; Young, P.M.; Kashyap, R.; Lieske, J.C. Evaluating Muscle Mass by Using Markers of Kidney Function: Development of the Sarcopenia Index. Crit. Care Med. 2017, 45, e23–e29. [Google Scholar] [CrossRef]
  150. Kashani, K.; Sarvottam, K.; Pereira, N.L.; Barreto, E.F.; Kennedy, C.C. The sarcopenia index: A novel measure of muscle mass in lung transplant candidates. Clin. Transplant. 2018, 32, e13182. [Google Scholar] [CrossRef]
  151. Barreto, E.F.; Poyant, J.O.; Coville, H.H.; Dierkhising, R.A.; Kennedy, C.C.; Gajic, O.; Nystrom, E.M.; Takahashi, N.; Moynagh, M.R.; Kashani, K.B. Validation of the sarcopenia index to assess muscle mass in the critically ill: A novel application of kidney function markers. Clin. Nutr. 2019, 38, 1362–1367. [Google Scholar] [CrossRef]
  152. Hirai, K.; Tanaka, A.; Homma, T.; Goto, Y.; Akimoto, K.; Uno, T.; Yoshitaka, U.; Miyata, Y.; Inoue, H.; Ohta, S.; et al. Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with chronic obstructive pulmonary disease. Clin. Nutr. 2021, 40, 1274–1280. [Google Scholar] [CrossRef]
  153. Tang, T.; Zhuo, Y.; Xie, L.; Wang, H.; Yang, M. Sarcopenia index based on serum creatinine and cystatin C is associated with 3-year mortality in hospitalized older patients. Sci. Rep. 2020, 10, 1260. [Google Scholar] [CrossRef]
  154. He, Q.; Jiang, J.; Xie, L.; Zhang, L.; Yang, M. A sarcopenia index based on serum creatinine and cystatin C cannot accurately detect either low muscle mass or sarcopenia in urban community-dwelling older people. Sci. Rep. 2018, 8, 11534. [Google Scholar] [CrossRef]
  155. Singhal, S.; Singh, S.; Upadhyay, A.D.; Dwivedi, S.N.; Das, C.J.; Mohta, S.; Chatterjee, P.; Dey, A.B.; Chakrawarty, A. Serum creatinine and cystatin C-based index can be a screening biomarker for sarcopenia in older population. Eur. Geriatr. Med. 2019, 10, 625–630. [Google Scholar] [CrossRef]
  156. Osaka, T.; Hamaguchi, M.; Hashimoto, Y.; Ushigome, E.; Tanaka, M.; Yamazaki, M.; Fukui, M. Decreased the creatinine to cystatin C ratio is a surrogate marker of sarcopenia in patients with type 2 diabetes. Diabetes Res. Clin. Pract. 2018, 139, 52–58. [Google Scholar] [CrossRef]
  157. Shin, J.Y. Low serum creatinine to cystatin C ratio is independently associated with sarcopenia and high carotid plaque score in patients with type 2 diabetes. Nutr. Metab. Cardiovasc. Dis. 2022, 32, 1454–1462. [Google Scholar] [CrossRef]
  158. Hashimoto, Y.; Takahashi, F.; Okamura, T.; Osaka, T.; Okada, H.; Senmaru, T.; Majima, S.; Ushigome, E.; Nakanishi, N.; Asano, M.; et al. Relationship between serum creatinine to cystatin C ratio and subclinical atherosclerosis in patients with type 2 diabetes. BMJ Open Diabetes Res. Care 2022, 10, e002910. [Google Scholar] [CrossRef]
  159. Komorita, Y.; Iwase, M.; Fujii, H.; Ide, H.; Ohkuma, T.; Jodai-Kitamura, T.; Sumi, A.; Yoshinari, M.; Nakamura, U.; Kitazono, T. The serum creatinine to cystatin C ratio predicts bone fracture in patients with type 2 diabetes: The Fukuoka Diabetes Registry. Diabetes Res. Clin. Pract. 2018, 146, 202–210. [Google Scholar] [CrossRef]
  160. Dai, H.; Xu, J. Creatinine-to-cystatin C ratio as a marker of sarcopenia for identifying osteoporosis in male patients with type 2 diabetes mellitus. BMC Musculoskelet. Disord. 2022, 23, 672. [Google Scholar] [CrossRef]
  161. Wei, W.; Li, S.; Liu, J.; Liu, Y.; Chen, K.; Chen, S.; Tu, M.; Chen, H. Prognostic value of creatinine-to-cystatin c ratio in patients with type 2 diabetes mellitus: A cohort study. Diabetol. Metab. Syndr. 2022, 14, 176. [Google Scholar] [CrossRef] [PubMed]
  162. Nguyen, T.M.D. Adiponectin: Role in Physiology and Pathophysiology. Int. J. Prev. Med. 2020, 11, 136. [Google Scholar] [CrossRef] [PubMed]
  163. Chen, M.B.; McAinch, A.J.; Macaulay, S.L.; Castelli, L.A.; O’Brien, P.E.; Dixon, J.B.; Cameron-Smith, D.; Kemp, B.E.; Steinberg, G.R. Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics. J. Clin. Endocrinol. Metab. 2005, 90, 3665–3672. [Google Scholar] [CrossRef] [PubMed]
  164. Wang, X.; Hu, Z.; Hu, J.; Du, J.; Mitch, W.E. Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology 2006, 147, 4160–4168. [Google Scholar] [CrossRef]
  165. Perakakis, N.; Farr, O.M.; Mantzoros, C.S. Leptin in Leanness and Obesity: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2021, 77, 745–760. [Google Scholar] [CrossRef]
  166. Beberashvili, I.; Azar, A.; Khatib, A.; Abu Hamad, R.; Neheman, A.; Efrati, S.; Doenyas-Barak, K. Sarcopenic Obesity Versus Nonobese Sarcopenia in Hemodialysis Patients: Differences in Nutritional Status, Quality of Life, and Clinical Outcomes. J. Ren. Nutr. 2023, 33, 147–156. [Google Scholar] [CrossRef]
  167. Sahin-Efe, A.; Upadhyay, J.; Ko, B.J.; Dincer, F.; Park, K.H.; Migdal, A.; Vokonas, P.; Mantzoros, C. Irisin and leptin concentrations in relation to obesity, and developing type 2 diabetes: A cross sectional and a prospective case-control study nested in the Normative Aging Study. Metabolism 2018, 79, 24–32. [Google Scholar] [CrossRef]
  168. Liu, W.; Zhou, X.; Li, Y.; Zhang, S.; Cai, X.; Zhang, R.; Gong, S.; Han, X.; Ji, L. Serum leptin, resistin, and adiponectin levels in obese and non-obese patients with newly diagnosed type 2 diabetes mellitus: A population-based study. Medcine 2020, 99, e19052. [Google Scholar] [CrossRef]
  169. Zhao, Y.; Li, H. Association of serum leptin and insulin levels among type 2 diabetes mellitus patients: A case-control study. Medcine 2022, 101, e31006. [Google Scholar] [CrossRef]
  170. Mohammed Saeed, W.; Nasser Binjawhar, D. Association of Serum Leptin and Adiponectin Concentrations with Type 2 Diabetes Biomarkers and Complications Among Saudi Women. Diabetes Metab. Syndr. Obes. 2023, 16, 2129–2140. [Google Scholar] [CrossRef]
  171. Moonishaa, T.M.; Nanda, S.K.; Shamraj, M.; Sivaa, R.; Sivakumar, P.; Ravichandran, K. Evaluation of Leptin as a Marker of Insulin Resistance in Type 2 Diabetes Mellitus. Int. J. Appl. Basic. Med. Res. 2017, 7, 176–180. [Google Scholar] [CrossRef]
  172. Nan, J.; Zhang, X.; Li, D.; Jin, M.; Guo, G.; Dong, J.; Li, X. Effect of Leptin Levels of Type 2 Diabetes Mellitus and Diabetic Complications. Clin. Investig. Med. 2022, 45, E32–E46. [Google Scholar] [CrossRef]
  173. Vavruch, C.; Länne, T.; Fredrikson, M.; Lindström, T.; Östgren, C.J.; Nystrom, F.H. Serum leptin levels are independently related to the incidence of ischemic heart disease in a prospective study of patients with type 2 diabetes. Cardiovasc. Diabetol. 2015, 14, 62. [Google Scholar] [CrossRef]
  174. Onyemelukwe, O.U.; Ogoina, D.; Onyemelukwe, G.C. Leptin concentrations in type 2 diabetes and non-diabetes Nigerian-Africans. Am. J. Cardiovasc. Dis. 2020, 10, 444–454. [Google Scholar]
  175. Chen, G.C.; Qin, L.Q.; Ye, J.K. Leptin levels and risk of type 2 diabetes: Gender-specific meta-analysis. Obes. Rev. 2014, 15, 134–142. [Google Scholar] [CrossRef]
  176. Li, Y.; Chen, X.; Gong, X.; Yao, J.; He, D.; Du, W. Effect of Gender on Serum Leptin in Type 2 Diabetes Mellitus: A System Review and Meta-Analysis. Comput. Math. Methods Med. 2022, 2022, 4875799. [Google Scholar] [CrossRef]
  177. Wu, P.; Wen, W.; Li, J.; Xu, J.; Zhao, M.; Chen, H.; Sun, J. Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 Diabetes. Horm. Metab. Res. 2019, 51, 487–494. [Google Scholar] [CrossRef]
  178. Ida, S.; Murata, K.; Kaneko, R. Effects of pioglitazone treatment on blood leptin levels in patients with type 2 diabetes. J. Diabetes Investig. 2018, 9, 917–924. [Google Scholar] [CrossRef]
  179. Yoshida, T.; Delafontaine, P. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells 2020, 9, 1970. [Google Scholar] [CrossRef]
  180. Giovannini, S.; Marzetti, E.; Borst, S.E.; Leeuwenburgh, C. Modulation of GH/IGF-1 axis: Potential strategies to counteract sarcopenia in older adults. Mech. Ageing Dev. 2008, 129, 593–601. [Google Scholar] [CrossRef]
  181. Jiang, J.J.; Chen, S.M.; Chen, J.; Wu, L.; Ye, J.T.; Zhang, Q. Serum IGF-1 levels are associated with sarcopenia in elderly men but not in elderly women. Aging Clin. Exp. Res. 2022, 34, 2465–2471. [Google Scholar] [CrossRef]
  182. Zhou, Y.L.; Liu, S.Q.; Yuan, B.; Lu, N. The expression of insulin-like growth factor-1 in senior patients with diabetes and dementia. Exp. Ther. Med. 2017, 13, 103–106. [Google Scholar] [CrossRef]
  183. Rui-Hua, C.; Yong-de, P.; Xiao-Zhen, J.; Chen, J.; Bin, Z. Decreased Levels of Serum IGF-1 and Vitamin D Are Associated With Cognitive Impairment in Patients with Type 2 Diabetes. Am. J. Alzheimers Dis. Other Demen 2019, 34, 450–456. [Google Scholar] [CrossRef]
  184. Chen, H.S.; Wu, T.E.; Hsiao, L.C.; Lin, S.H. Interaction between glycaemic control and serum insulin-like growth factor 1 on the risk of retinopathy in type 2 diabetes. Eur. J. Clin. Investig. 2012, 42, 447–454. [Google Scholar] [CrossRef]
  185. Wang, J.; Chen, X.; Zhao, Y. Serum GLP-1 and IGF-1 levels are candidate diagnostic biomarkers for type 2 diabetes mellitus complicated by coronary heart disease. Am. J. Transl. Res. 2023, 15, 2033–2039. [Google Scholar]
  186. Yamada, M.; Nishiguchi, S.; Fukutani, N.; Aoyama, T.; Arai, H. Mail-Based Intervention for Sarcopenia Prevention Increased Anabolic Hormone and Skeletal Muscle Mass in Community-Dwelling Japanese Older Adults: The INE (Intervention by Nutrition and Exercise) Study. J. Am. Med. Dir. Assoc. 2015, 16, 654–660. [Google Scholar] [CrossRef]
  187. Yanagita, I.; Fujihara, Y.; Kitajima, Y.; Tajima, M.; Honda, M.; Kawajiri, T.; Eda, T.; Yonemura, K.; Yamaguchi, N.; Asakawa, H.; et al. A High Serum Cortisol/DHEA-S Ratio Is a Risk Factor for Sarcopenia in Elderly Diabetic Patients. J. Endocr. Soc. 2019, 3, 801–813. [Google Scholar] [CrossRef]
  188. Rasmussen, J.J.; Selmer, C.; Frøssing, S.; Schou, M.; Faber, J.; Torp-Pedersen, C.; Gislason, G.H.; Køber, L.; Hougaard, D.M.; Cohen, A.S.; et al. Endogenous Testosterone Levels Are Associated with Risk of Type 2 Diabetes in Women without Established Comorbidity. J. Endocr. Soc. 2020, 4, bvaa050. [Google Scholar] [CrossRef]
  189. Veronese, N.; Trevisan, C.; De Rui, M.; Bolzetta, F.; Maggi, S.; Zambon, S.; Corti, M.C.; Baggio, G.; Perissinotto, E.; Crepaldi, G.; et al. Serum Dehydroepiandrosterone Sulfate and Risk for Type 2 Diabetes in Older Men and Women: The Pro.V.A Study. Can. J. Diabetes 2016, 40, 158–163. [Google Scholar] [CrossRef]
  190. El-Sakka, A.I.; Sayed, H.M.; Tayeb, K.A. Type 2 diabetes-associated androgen alteration in patients with erectile dysfunction. Int. J. Androl. 2008, 31, 602–608. [Google Scholar] [CrossRef]
  191. Fukui, M.; Kitagawa, Y.; Nakamura, N.; Kadono, M.; Hasegawa, G.; Yoshikawa, T. Association between urinary albumin excretion and serum dehydroepiandrosterone sulfate concentration in male patients with type 2 diabetes: A possible link between urinary albumin excretion and cardiovascular disease. Diabetes Care 2004, 27, 2893–2897. [Google Scholar] [CrossRef]
  192. Kanazawa, I.; Yamaguchi, T.; Sugimoto, T. Serum insulin-like growth factor-I is negatively associated with serum adiponectin in type 2 diabetes mellitus. Growth Horm. IGF Res. 2011, 21, 268–271. [Google Scholar] [CrossRef]
  193. Zhang, X.; Huang, Y.; Xu, N.; Feng, W.; Qiao, J.; Liu, M. Low serum dehydroepiandrosterone levels are associated with diabetic retinopathy in patients with type 2 diabetes mellitus. J. Diabetes Investig. 2023, 14, 675–685. [Google Scholar] [CrossRef]
  194. Kanazawa, I.; Yamaguchi, T.; Yamamoto, M.; Yamauchi, M.; Kurioka, S.; Yano, S.; Sugimoto, T. Serum DHEA-S level is associated with the presence of atherosclerosis in postmenopausal women with type 2 diabetes mellitus. Endocr. J. 2008, 55, 667–675. [Google Scholar] [CrossRef]
  195. Fukui, M.; Kitagawa, Y.; Nakamura, N.; Kadono, M.; Yoshida, M.; Hirata, C.; Wada, K.; Hasegawa, G.; Yoshikawa, T. Serum dehydroepiandrosterone sulfate concentration and carotid atherosclerosis in men with type 2 diabetes. Atherosclerosis 2005, 181, 339–344. [Google Scholar] [CrossRef]
  196. Zhang, X.; Xiao, J.; Li, X.; Cui, J.; Wang, K.; He, Q.; Liu, M. Low Serum Dehydroepiandrosterone Is Associated With Diabetic Kidney Disease in Men With Type 2 Diabetes Mellitus. Front. Endocrinol. 2022, 13, 915494. [Google Scholar] [CrossRef]
  197. Zhang, X.; Xiao, J.; Liu, T.; He, Q.; Cui, J.; Tang, S.; Li, X.; Liu, M. Low Serum Dehydroepiandrosterone and Dehydroepiandrosterone Sulfate Are Associated With Coronary Heart Disease in Men With Type 2 Diabetes Mellitus. Front. Endocrinol. 2022, 13, 890029. [Google Scholar] [CrossRef]
  198. Tuttle, C.S.L.; Thang, L.A.N.; Maier, A.B. Markers of inflammation and their association with muscle strength and mass: A systematic review and meta-analysis. Ageing Res. Rev. 2020, 64, 101185. [Google Scholar] [CrossRef]
  199. Anita, N.Z.; Zebarth, J.; Chan, B.; Wu, C.Y.; Syed, T.; Shahrul, D.; Nguyen, M.M.; Pakosh, M.; Herrmann, N.; Lanctôt, K.L.; et al. Inflammatory markers in type 2 diabetes with vs. without cognitive impairment; a systematic review and meta-analysis. Brain Behav. Immun. 2022, 100, 55–69. [Google Scholar] [CrossRef]
  200. Nguyen, M.M.; Perlman, G.; Kim, N.; Wu, C.Y.; Daher, V.; Zhou, A.; Mathers, E.H.; Anita, N.Z.; Lanctôt, K.L.; Herrmann, N.; et al. Depression in type 2 diabetes: A systematic review and meta-analysis of blood inflammatory markers. Psychoneuroendocrinology 2021, 134, 105448. [Google Scholar] [CrossRef]
  201. Karbalaee-Hasani, A.; Khadive, T.; Eskandari, M.; Shahidi, S.; Mosavi, M.; Nejadebrahimi, Z.; Khalkhali, L.; Sangdari, A.; Mohammadi, D.; Soltani, A.; et al. Effect of Metformin on Circulating Levels of Inflammatory Markers in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Ann. Pharmacother. 2021, 55, 1096–1109. [Google Scholar] [CrossRef]
  202. Hejazi, K.; Mohammad Rahimi, G.R.; Rosenkranz, S.K. Effects of Exercise Training on Inflammatory and Cardiometabolic Risk Biomarkers in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Biol. Res. Nurs. 2023, 25, 250–266. [Google Scholar] [CrossRef]
  203. Chen, X.; Sun, X.; Wang, C.; He, H. Effects of Exercise on Inflammatory Cytokines in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials. Oxid. Med. Cell. Longev. 2020, 2020, 6660557. [Google Scholar] [CrossRef]
  204. Yang, W.; Jiao, H.; Xue, Y.; Wang, L.; Zhang, Y.; Wang, B.; Teng, Z.; Li, J.; Zhao, H.; Liu, C. A Meta-Analysis of the Influence on Inflammatory Factors in Type 2 Diabetes among Middle-Aged and Elderly Patients by Various Exercise Modalities. Int. J. Environ. Res. Public Health 2023, 20, 1783. [Google Scholar] [CrossRef]
Table 1. Changes in biomarker concentrations in sarcopenia and in T2DM (based on [16]).
Table 1. Changes in biomarker concentrations in sarcopenia and in T2DM (based on [16]).
BiomarkerModification in SarcopeniaModification in T2DMMechanism of Action/Comments
Assessment of musculoskeletal status
Myokines
MSTN
(GDF-8)		↓
conflicting sex-dependent data [55]		↑ [56,57]Mechanism: muscle protein turnover
Increases with higher muscle mass
LC-MS/MS measurement methods should be favored
FST↑ [58]↑ [59,60]Mechanism: muscle protein turnover
Suggested to be assessed together with MSTN
MSTN and FST are acutely increased after exercise but return to baseline within 24 h
Irisin↓ [61,62,63,64,65,66]↓ [67,68]Mechanism: muscle protein turnover
Neuromuscular junction
BDNF↓ [69,70]↓ [71]Mechanism: remodelling of neuromuscular junction
Other
PIIINPlimited number of studies,
conflicting data between sex groups [72,73]		probably no correlation [74]Mechanism: muscle collagen turnover
SI↓ [75,76]probably ↓
a limited number of studies [77]		Developed to reflect muscle mass,
reclassified as the marker of muscle turnover subclass;
= serum creatinine (mg/dL)/serum cystatin C (mg/L)) × 100
Assessment of causal factors
Adipokines
Adiponectin↑ [78]↓ [79]Anti-inflammatory factor
Mechanism: muscle–fat crosstalk
Leptinlimited number of studies,
conflicting data [80,81,82,83]		↑ [84,85,86,87]Relevant in sarcopenic obesity
Hormones
IGF-1↓ [88,89,90,91,92]↓ [93,94]
conflicting data [95,96,97]		Age-related differences
Anabolic
DHEAS↓ [58,98,99]↓ [100,101,102]Sex-dependent differences
Anabolic
Inflammatory markers
CRP↑ [103]↑ [104,105]Mechanism: low-grade chronic inflammation
Preferred use of ultrasensitive method
IL-6probably no basal modification [103]↑ [104,105]Mechanism: low-grade chronic inflammation
Increases associated with lower muscle strength and mass
TNF-αprobably no basal modification [103]↑ [105]Mechanism: low-grade chronic inflammation
Increases associated with lower muscle strength and mass
Where: ↑, increased concentration; ↓, decreased concentration; BDNF, brain-derived neurotrophic factor; CRP, C-reactive protein; DHEAS, dehydroepiandrosterone sulphate; FST, follistatin; GDF-8, growth differentiation factor-8; GDNF, glial cell line-derived neurotrophic factor; IGF-1, insulin-like growth factor; IL-6, interleukin-6; LC-MS/MS, liquid chromatography–tandem mass spectrometry; MSTN, myostatin; PIIINP, procollagen type III N-terminal peptide; SI, Sarcopenia Index; T2DM, type 2 diabetes mellitus.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Rentflejsz, J.; Wojszel, Z.B. Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related Biomarkers. J. Clin. Med. 2024, 13, 1107. https://doi.org/10.3390/jcm13041107

AMA Style

Rentflejsz J, Wojszel ZB. Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related Biomarkers. Journal of Clinical Medicine. 2024; 13(4):1107. https://doi.org/10.3390/jcm13041107

Chicago/Turabian Style

Rentflejsz, Justyna, and Zyta Beata Wojszel. 2024. "Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related Biomarkers" Journal of Clinical Medicine 13, no. 4: 1107. https://doi.org/10.3390/jcm13041107

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop